The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.
Anil Shankar, Adria Warren, and Jordan Smiley
Advertisement
Articles by Anil Shankar, Adria Warren, and Jordan Smiley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cencora Accelerates Global 3PL Expansion With Major Investments in Cold Chain and Specialty Logistics
2
Pharma Pulse: Pazdur Retires from FDA, While Public Trusts AMA Over CDC on Vaccines, and New Data Redefines Adherence as an Emotional Crisis
3
Strive Pharmacy Breaks Ground on Arizona HQ
4
CNPV Limits May Not Slow Collaboration or Commercialization
5
